BIO 2013: Biosimilars, Drug Pricing, Business Development And Innovation
Executive Summary
Pharma and biotech leaders discussed the biosimilars landscape, paying for innovation beyond rare disease drugs, emerging markets and partnering trends at BIO 2013 in Chicago.
You may also be interested in...
BIO 2013 Wednesday Roundup: Roche Partnering, Crowdfunding, Alzheimer’s and Deal Trend Data
Our survey of news and notes from the third day of the BIO 2013 conference includes insights from panel discussions about the environments for licensing deals and Alzheimer’s disease research, an interview with a Roche exec about the company’s partnering strategy, and news about a crowdfunding portal that will connect VCs and companies with accredited individual investors.
Better Late Than Never, J&J’s Innovation Centers Start Opening For Business
J&J’s new London innovation center has just opened and Boston, San Francisco and Shanghai sites are soon to follow. A J&J executive providing an update in NY faced questions from a somewhat skeptical audience of potential customers, revealing nuances and new information about how the centers will operate.
J&J’s New Innovation Centers Test Immersion Theory Of Access
Johnson & Johnson executives including Pharma Chairman and CSO Paul Stoffels explain how building a presence in innovation’s backyard will allow the health care giant to more easily and quickly access new assets and technologies. Can proximity to innovation make J&J more innovative?